| Market revenue in 2025 | USD 67.0 billion |
| Market revenue in 2033 | USD 107.1 billion |
| Growth rate | 6.1% (CAGR from 2026 to 2033) |
| Largest segment | Conventional drugs (small molecules) |
| Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD billion |
| Market segmentation | Conventional Drugs (Small Molecules), Biologics & Biosimilars (Large Molecules) |
| Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
The UK pharmaceutical market driven by rising healthcare spending on pharmaceutical products. In 2023, the UK’s healthcare expenditure was estimated at approximately USD 360.31 billion, reflecting a 5.6% nominal increase from the previous year.
However, after adjusting for inflation, total healthcare spending declined by 1.4%. Healthcare expenditure as a percentage of GDP slightly decreased to 10.9% from 11.1% in 2022, as economic growth outpaced healthcare spending. Government-funded healthcare expenditure accounted for around USD 294.92 billion, representing a real-term decline of 2.1%.
One of the most significant shifts in the sector was a 16.6% reduction in real-term pharmaceutical spending, primarily due to lower costs associated with the COVID-19 vaccination program. Meanwhile, long-term health and social care spending increased by 2.8%, underscoring the growing demand for sustained healthcare support, particularly for chronic conditions and aging-related care.
Publish Date: Apr 10, 2026
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmaceutical Market Outlook will help companies and investors design strategic landscapes.
Conventional Drugs (Small Molecules) was the largest segment with a revenue share of 56.87% in 2025.
Horizon Databook has segmented the U.K. pharmaceutical market based on conventional drugs (small molecules), biologics & biosimilars (large molecules) covering the revenue growth of each sub-segment from 2021 to 2033.
The UK pharmaceutical market driven by rising healthcare spending on pharmaceutical products. In 2023, the UK’s healthcare expenditure was estimated at approximately USD 360.31 billion, reflecting a 5.6% nominal increase from the previous year.
However, after adjusting for inflation, total healthcare spending declined by 1.4%. Healthcare expenditure as a percentage of GDP slightly decreased to 10.9% from 11.1% in 2022, as economic growth outpaced healthcare spending. Government-funded healthcare expenditure accounted for around USD 294.92 billion, representing a real-term decline of 2.1%.
One of the most significant shifts in the sector was a 16.6% reduction in real-term pharmaceutical spending, primarily due to lower costs associated with the COVID-19 vaccination program. Meanwhile, long-term health and social care spending increased by 2.8%, underscoring the growing demand for sustained healthcare support, particularly for chronic conditions and aging-related care.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Pharmaceutical Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Pharmaceutical Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
